Research Letter
Synthesis and Biological Evaluation of 7-O-Modified Formononetin Derivatives
Table 1
Antiproliferative activity of the synthesized compounds.
| | Compounds | IC50 (μg/mL) | | Jurkat1 | HepG-22 |
| | 1 | 23.52 | 73.03 | | 2a
| 48.04 | >100.00 | | 2b | 0.21 | 4.14 | | 2c
| 9.50 | 7.18 | | 3a | 13.93 | 5.57 | | 3b | 1.82 | 3.24 | | 3c | >100.00 | 2.67 | | 3d | 3.70 | 8.14 | | 3e | 12.21 | 7.15 | | 3f
| 16.49 | 7.54 | | 4a
| 0.41 | 6.14 | | 4b | 5.32 | 8.58 | | 4c
| 16.44 | 52.21 | | 4d | 18.08 | 5.90 | | 4e | 3.49 | 57.82 | | 5a
| 1.94 | 6.54 | | 5b | >100.00 | 7.52 | | 5c
| 0.64 | 4.94 | | 5d | 1.27 | 1.49 | | 5e | 1.35×10-4 | 13.14 | | 5f
| 7.11 | 13.53 |
| | 5-fluorouracil | 18.41 | 2.50 |
|
|
1Jurkat: Human T cell lymphoblast-like cell line.2HepG-2: Human hepatocellular liver carcinoma cell line.
|
